Zydus Lifesciences Secures US FDA Green Light for Eltrombopag Tablets

HEALTHCAREBIOTECH

Overview

Zydus Lifesciences announced final US FDA approval for its Eltrombopag Tablets, a critical treatment for low platelet counts. This clearance unlocks access to a U.S. market where the drug generated $1.26 billion in annual sales. The approval marks the company's 429th USFDA clearance, underscoring its strong global regulatory compliance.

US FDA Grants Final Approval to Zydus Lifesciences

Zydus Lifesciences Ltd. received final approval from the U.S. Food and Drug Administration for its Eltrombopag Tablets on Thursday, January 15. The drug, available in 12.5 mg, 25 mg, 50 mg, and 75 mg strengths, is prescribed for thrombocytopenia, a condition characterized by dangerously low platelet counts.

Therapeutic Efficacy and Mechanism

Eltrombopag functions by stimulating the bone marrow cells to produce more platelets. This increased production helps mitigate the associated risks of bleeding in patients with specific blood disorders. The tablets will be manufactured at the company's SEZ formulation facility in Ahmedabad.

Significant Market Opportunity

The U.S. market presents a substantial revenue stream for Eltrombopag. According to IQVIA data for November 2025, the drug recorded annual sales of $1,262.5 million in the region. This approval is expected to bolster Zydus Lifesciences' market presence and revenue.

Regulatory Milestones and Stock Performance

This latest approval brings Zydus Lifesciences' cumulative USFDA clearances to 429. The company has filed a total of 505 Abbreviated New Drug Applications (ANDAs) since its filing initiation in FY2003-04. In recent trading, shares of Zydus Lifesciences Ltd. settled 1.74% lower on Wednesday, closing at ₹885.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.